Meta-analysis of 11 studies of anti-CGRP (receptor) antibodies used for 12 months or more for migraine prevention: pooled discontinuation was 23% for any reason and 3% for adverse events. All studies had severe risk of bias.
Meta-analysisn = 11 studies
Hoehne et al. Decoding the long-term safety of anti-CGRP (receptor) mAbs: a meta-analysis and systematic review